Cardiovascular Calcification Drug Pipeline Analysis Report 2025

Cardiovascular calcification refers to the buildup of calcium phosphate in the walls of the arteries and heart valves. Also known as the hardening of the arteries, this condition can lead to serious cardiovascular events including heart disease. Atherosclerosis and chronic kidney disease are increasingly contributing to the rising cases of vascular calcification, which is likely to augment the demand for effective cardiovascular calcification drugs.

Report Coverage

The Cardiovascular Calcification Drug Pipeline Insight Report by the publisher gives comprehensive insights into cardiovascular calcification therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cardiovascular calcification. The cardiovascular calcification report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cardiovascular calcification pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with cardiovascular calcification treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cardiovascular calcification.

Cardiovascular Calcification Drug Pipeline Outlook

Cardiovascular calcification is characterized by mineral deposits in heart valve leaflets and vessel walls. Coronary artery calcification causes the arteries to become stiff, which puts the affected patient at a higher risk for cardiovascular issues. According to a cross-sectional study published in BMC Cardiovascular Disorders (2022), the overall prevalence of vascular calcification was estimated to be 24.39% in the general population.

Cardiovascular calcification therapeutics include Vitamin D receptor agonists that can help in the treatment of vitamin D deficiency and secondary hyperparathyroidism, thereby preventing calcification. Calcimimetics, sodium thiosulfate, and calcium channel blockers are some of the common medications for addressing vascular calcification. Additionally, advancements in imaging techniques and biomarkers, along with adherence to cardiovascular calcification treatment guidelines, are expected to improve patient outcomes and aid pipeline expansion in the coming years.

Cardiovascular Calcification Epidemiology

Cardiovascular calcification is age- and gender-dependent. Studies show that over 90% of men and 67% of women who are older than 70 years are affected by coronary artery calcification. It is also observed that people with chronic kidney disease, diabetes, high body mass index, or high blood pressure, among others, are more prone to developing cardiovascular calcification.

Cardiovascular Calcification - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of cardiovascular calcification drug candidates based on several segmentations including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Monoclonal Antibody
• Peptides
• Polymer
• Small Molecule
• Gene Therapy

By Route of Administration

• Oral
• Parenteral
• Others

Cardiovascular Calcification - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of cardiovascular calcification emerging drugs undergoing clinical development.

Cardiovascular Calcification - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under cardiovascular calcification pipeline analysis include monoclonal antibody, peptides, polymer, small molecule, and gene therapy. The cardiovascular calcification report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cardiovascular calcification.

Cardiovascular Calcification Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the cardiovascular calcification drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cardiovascular calcification therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cardiovascular calcification clinical trials:

• REDNVIA Co., Ltd.
• Novartis Pharmaceuticals
• Inozyme Pharma
• Edwards Lifesciences
• Bolt Medical

Cardiovascular Calcification - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: DA-1229

(Evogliptin)
Sponsored by REDNVIA Co., Ltd., the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the efficacy and safety of the cardiovascular calcification drug candidate Evogliptin in patients with calcific aortic valve disease with mild to moderate aortic stenosis. The study is under Phase II/III clinical development and has an estimated 867 participants.

Drug: Metformin

The purpose of this double-blind randomized controlled trial is to examine the efficacy of metformin on peripheral arterial calcification in type 1 diabetes patients. The interventional study has enrolled about 230 subjects and is expected to be completed by February 2025.

Reasons To Buy This Report

The Cardiovascular Calcification Drug Report provides a strategic overview of the latest and future landscape of treatments for cardiovascular calcification. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within cardiovascular calcification pipeline insights.

Key Questions Answered in the Cardiovascular Calcification - Pipeline Insight Report

• What is the current landscape of cardiovascular calcification pipeline drugs?
• How many companies are developing cardiovascular calcification drugs?
• How many phase III and phase IV drugs are currently present in cardiovascular calcification pipeline drugs?
• What is the efficacy and safety profile of drug candidates for cardiovascular calcification?
• What are the opportunities and challenges present in the cardiovascular calcification drug pipeline landscape?
• Which company is conducting major trials for cardiovascular calcification drugs?
• What geographies are covered for cardiovascular calcification clinical trials?
• What are emerging trends in cardiovascular calcification clinical trials?

This product will be delivered within 3-5 business days.